Comparison of in-vitro pharmacodynamics of once and twice daily ciprofloxacin (Q43820901)

27 November 2017

title

Comparison of in-vitro pharmacodynamics of once and twice daily ciprofloxacin (English)

1 reference

27 November 2017

1 reference

Bowker KE

1

1 reference

27 November 2017

Wootton M

2

1 reference

27 November 2017

Rogers CA

3

1 reference

27 November 2017

Lewis R

4

1 reference

27 November 2017

Holt HA

5

1 reference

27 November 2017

MacGowan AP

6

1 reference

27 November 2017

language of work or name

English

0 references

publication date

1 November 1999

1 reference

Journal of Antimicrobial Chemotherapy

27 November 2017

published in

1 reference

27 November 2017

volume

44

1 reference

27 November 2017

issue

5

1 reference

27 November 2017

page(s)

661-667

1 reference

The post-antibiotic effect

27 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.5.661

Correlation between in vitro and in vivo activity of antimicrobial agents against gram-negative bacilli in a murine infection model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.5.661

Impact of the dosage schedule on the efficacy of ceftazidime, gentamicin and ciprofloxacin in Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.5.661

Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.5.661

Evaluation of the efficacy of ciprofloxacin against Streptococcus pneumoniae by using a mouse protection model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.5.661

Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.5.661

Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.5.661

In-vitro activity of cefpodoxime against 1834 isolates from domiciliary infections at 20 UK centres.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.5.661

Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with rifampin, against methicillin-susceptible and -resistant Staphylococcus aureus in an in vitro infection model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.5.661

Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.5.661

Pharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa for which MICs are similar

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2F44.5.661

21 January 2018

Identifiers

DOI

10.1093/JAC/44.5.661

1 reference

27 November 2017

1 reference